← Human Trials & Peer-Reviewed Studies
CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial
Plain-language guide to PMID 30240937 (2018): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide).
Key Facts
- PMID
- 30240937
- Journal
- Osteoarthritis and cartilage
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Jin Y et al. (12 authors)
- DOI
- 10.1016/j.joca.2018.08.019
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide).
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Secondary endpoints included WOMAC function subscore and Patient Global Assessment (PGA) of OA.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).
The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.
Running at several centres spread the CGRP (Calcitonin Gene-Related Peptide) study over different clinics and patient groups.
The primary outcome was change from baseline at Week 8 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore measured by 100 mm visual analog scale (VAS).
Safety and tolerability were also assessed.
What Was Measured
The subject headings attached to it are Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Celecoxib, Osteoarthritis, Knee, Pain, Pain Management and Pain Measurement.
Author keywords: CGRP, Clinical trial and Monoclonal antibody.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Osteoarthritis and cartilage), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.